News/ News/ R&D UCB’s bimekizumab tops J&J’s Stelara in psoriasis study Phil Taylor bimekizumab, IL-17A, IL-17F, psoriasis, UCB 0 Comment The first phase 3 data with UCB’s key pipeline drug bimekizumab show that it hit all its efficacy Share X UCB’s bimekizumab tops J&J’s Stelara in psoriasis study https://pharmaphorum.com/news/ucbs-bimekizumab-tops-jjs-stelara-in-psoriasis-study/
